Plasma Level of Adiponectin in Chinese with Metabolic Syndrome and Ischemic Cerebral Vascular Disease

• Main Authors: Liang-Lan Hsing, 幸良蘭
• Other Authors: Shyi-Jang Shin
• Format: Others
• Language: zh-TW
• Published: 2005
• Online Access: http://ndltd.ncl.edu.tw/handle/34024690468567178118

碩士 === 高雄醫學大學 === 醫學研究所碩士班 === 93 === Objectives: Adiponectin, an adipocyte derived peptide with anti-inflammatory and anti-therogenic effects, is known to protect against the initiation and progression of atherosclerosis. In this study, we investigate whether hypoadiponectinemia is present in patients with metabolic syndrome and ischemic cerebrovascular disease (CVD). Methods and Results: In this case–control study, plasma adiponectin concentration was measured by an ELISA method in type 2 diabetic and ischemic cerebrovascular disease. and healthy volunteers (controls group). The mean plasma level of adiponectin of the 106 patients with type 2 diabetic was significantly lower than that of 108 controls group (4.2±3.2 µg/mL versus 21.6 ±12.4 µg/mL, p<.0001). The plasma adiponectin levels remained significantly lower after adjustment for age, sex, BMI (body mass index), WHR (waist to hip ratio) and smoking status (4.3 µg/mL vs. 21.7 µg/mL, p<.0001)。 Plasma adiponectin level was positively correlated with age, total choleaterol, HDL-C (High density lipoprotein cholesterol) and LDL-C (Low density lipoprotein cholesterol) levels. In contrast, plasma adiponectin concentration was inversely correlated with smoking status, WHR, diastolic blood pressure (DBP), fasting plasma glucose (FPG), serum triglyceride (TG), and plasma hsCRP levels. Multiple linear regression analysis reverealed WHR, DBP, FPG, TG, HDL-C and hsCRP levels were independently associated with plasma adiponectin levels. The mean plasma level of adiponectin of 99 patients with ischemic cerebrovascular disease. was significantly lower than that of 108 controls group (4.6±4.4 µg/mL versus 21.6±12.4 µg/mL, p<.0001). The plasma adiponectin levels remained significantly lower after adjustment for age, sex, BMI, WHR, diabetes and smoking status (5.1 µg/mL vs 21.7 µg/mL, p<.0001).The mean plasma adiponectin level of men (20.6 ±12.9 µg/L) was not different from that of women (21.8±12.3 µg/L, p = ns). Logistic regression analysis found that BMI, WHR, SBP, DBP, FPG, TG, serum HDL-C and creatinine levels, smoking status, and plasma adiponectin and hsCRP levels to be predictors of ischemic cerebrovascular disease. Multiple logistic regression analysis revealed that DBP, serum FPG, HDL-C and creatinine levels, hsCRP, smoking status, and plasma adiponectin concentration to be independently correlated with ischemic cerebrovascular disease. Decreasing concentrations of adiponectin were independently and significantly associated with a higher risk of ischemic cerebrovascular disease when concentrations were analyzed both by quartile and as a continuous variable. The multiple logistic regression analysis adjusted odds ratios for ischemic cerebrovascular disease in the second, third, and fourth quartiles were 48.0 (95% CI,2.1–1092.7),673.5(95% CI, 74.1–6117.2), and 1163.2(95% CI,26.9–15046.4), respectively. In conclusion, the present report shows that plasma adiponectin concentration is low in patients with type 2 diabetes and ischemic cerebrovascular disease and it finds a possible close relationship between adiponectin–metabolic syndrome–inflammation and the development of atherosclerosis.